Peer-Reviewed Study Confirms VeriStrat® Test From Biodesix, Inc. Provides Useful Information for Physicians in Managing Patients With Lung Cancer

Published: Apr 02, 2013

BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc., a molecular diagnostic company dedicated to personalizing medicine, today announced the online release of a peer-reviewed study demonstrating that physicians are using the company's VeriStrat test to help guide treatment decisions for patients with advanced non-small lung cell cancer (NSCLC). Details of the study and its results appeared online ahead of print in Current Medical Research & Opinion.

Back to news